Bluebird gets new M&A bid, seeking to top private equity offernews2025-03-28T19:51:41+00:00March 28th, 2025|Endpoints News|
Novo makes oral obesity drug partnership with Lexicon worth up to $1Bnews2025-03-28T11:30:08+00:00March 28th, 2025|Endpoints News|
Before Alumis went public via IPO, it tried doing a reverse merger with Acelyrinnews2025-03-28T10:59:16+00:00March 28th, 2025|Endpoints News|
Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drugnews2025-03-28T10:53:30+00:00March 28th, 2025|Endpoints News|
Miga Health co-founder shares why he turned down new fundingnews2025-03-27T13:00:51+00:00March 27th, 2025|Endpoints News|
Alcon takes majority stake in Aurion, changes CEOsnews2025-03-27T01:24:07+00:00March 27th, 2025|Endpoints News|
WuXi Biologics’ licensing deals help offset Biosecure threat in the USnews2025-03-25T15:11:03+00:00March 25th, 2025|Endpoints News|
Merck and Hengrui strike $2B deal for Lipoprotein(a) drugnews2025-03-25T10:30:41+00:00March 25th, 2025|Endpoints News|
Novo Nordisk pays $200M upfront for United Laboratories International Holdings’ triple-G obesity shotnews2025-03-24T11:41:59+00:00March 24th, 2025|Endpoints News|
The buildup to Chimerix’s $935M cash exit to Jazznews2025-03-21T16:28:15+00:00March 21st, 2025|Endpoints News|
